Patent classifications
A61K36/69
TRADITIONAL CHINESE MEDICINE COMPOSITION WITH IMPROVING COGNITION EFFECT, PREPARATION METHOD THEREOF AND TRADITIONAL CHINESE MEDICINE PREPARATION
The present disclosure relates to the technical field of traditional Chinese medicine, and more specifically, to a traditional Chinese medicine composition with improving cognition effect, its preparation method and a traditional Chinese medicine preparation. In parts by weight, the traditional Chinese medicine composition is made from 1-20 parts of Gastrodiae Rhizoma, 1-15 parts of Polygala tenuifolia Willd., 1-30 parts of Acorus tatarinowii, 0.1-10 parts of Cistanche deserticola Ma, 0.1-10 parts of Rehmanniae Radix Praeparata, and 0.01-1 parts of curcumin. The pharmacodynamic substances of Gastrodiae Rhizoma, Polygala tenuifolia Willd., Acorus tatarinowii, Cistanche deserticola Ma and Rehmanniae Radix Praeparata are extracted completely, concentrated and dried as much as possible. The volatile oil of Acorus tatarinowii and curcumin are encapsulated and dried by the volatile oil encapsulation technology. The dry powder of the traditional Chinese medicine compound extract is evenly mixed with the volatile oil encapsulation compound.
Composition for preventing or alleviating hangover, containing <i>Longan arillus </i>extract
Provided are a pharmaceutical composition for preventing an alcoholic hangover or alleviating a hangover, comprising a Longan arillus extract as an active ingredient, and a food composition for alleviating a hangover, comprising a Longan arillus extract.
Composition for preventing or alleviating hangover, containing <i>Longan arillus </i>extract
Provided are a pharmaceutical composition for preventing an alcoholic hangover or alleviating a hangover, comprising a Longan arillus extract as an active ingredient, and a food composition for alleviating a hangover, comprising a Longan arillus extract.
Composition for preventing or alleviating hangover, containing <i>Longan arillus </i>extract
Provided are a pharmaceutical composition for preventing an alcoholic hangover or alleviating a hangover, comprising a Longan arillus extract as an active ingredient, and a food composition for alleviating a hangover, comprising a Longan arillus extract.
Lactic acid bacteria and anti-inflammatory method thereof
A food composition is disclosed which comprises the acid-resistant bacterial strain Lactobacillus acetotolerans LE36. The L. acetotolerans LE36 strain has anti-inflammatory properties. The food composition can be further provided as a pharmaceutical composition.
Lactic acid bacteria and anti-inflammatory method thereof
A food composition is disclosed which comprises the acid-resistant bacterial strain Lactobacillus acetotolerans LE36. The L. acetotolerans LE36 strain has anti-inflammatory properties. The food composition can be further provided as a pharmaceutical composition.
FREEZE-DRIED FORMULATION, PREPARATION METHOD AND APPLICATION THEREOF
A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.
FREEZE-DRIED FORMULATION, PREPARATION METHOD AND APPLICATION THEREOF
A freeze-dried formulation and a preparation method and an application thereof are provided. Triterpenoid saponin has a mass percentage of 0.004-95% in the freeze-dried formulation, a binding agent has a mass percentage of 0.01-99% in the freeze-dried formulation; the freeze-dried formulation is freeze-dried by a primary prepared solution containing the triterpenoid saponin and the binding agent; when the triterpenoid saponin has a mass percentage of 0.001%-50% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-50% in the primary prepared solution, and a mass of the triterpenoid saponin increases with an increase of a mass of the binding agent; and when the triterpenoid saponin has a mass percentage of 50%-95% in the primary prepared solution, the binding agent has a mass percentage of 0.01%-20% in the primary prepared solution, and the mass of triterpenoid saponin decreases with the increase of the mass of the binding agent.
POLYGALA EXTRACT FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
This invention relates to a method of treating Attention-Deficit Hyperactivity Disorder by orally administering to a subject a composition containing a Radix Polygalae (Polygala tenuifolia Willd) extract (such as PDC-1421). A solid dosage form of the composition can be prepared into the gelatin capsule. The oral administration of the composition in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extract.
POLYGALA EXTRACT FOR THE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
This invention relates to a method of treating Attention-Deficit Hyperactivity Disorder by orally administering to a subject a composition containing a Radix Polygalae (Polygala tenuifolia Willd) extract (such as PDC-1421). A solid dosage form of the composition can be prepared into the gelatin capsule. The oral administration of the composition in healthy volunteers was safe and well-tolerated for the daily dose from 380 mg to 3800 mg. The composition can be administered chronically over at least 25 days; the daily dose is administered once per day, twice per day, or three times per day, wherein each dose is 380-760 mg of the botanical extract.